Clinical Trials Browser

Phase 3 × Pathologic Complete Response × Bortezomib × Clear all

NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Phase 3 Unknown

Pathologic Complete Response, Multiple Myeloma